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Azoles are the mainstay of oral therapy for aspergil-
losis. Azole resistance in Aspergillus has been reported in-
frequently. The first resistant isolate in Manchester, UK, was 
detected in 1999. In a clinical collection of 519 A. fumiga-
tus isolates, the frequency of itraconazole resistance was 
5%, a significant increase since 2004 (p<0.001). Of the 34 
itraconazole-resistant isolates we studied, 65% (22) were 
cross-resistant to voriconazole and 74% (25) were cross-
resistant to posaconazole. Thirteen of 14 evaluable patients 
in our study had prior azole exposure; 8 infections failed 
therapy  (progressed),  and  5  failed  to improve  (remained 
stable). Eighteen amino acid alterations were found in the 
target enzyme, Cyp51A, 4 of which were novel. A population 
genetic analysis of microsatellites showed the existence of 
resistant mutants that evolved from originally susceptible 
strains, different cyp51A mutations in the same strain, and 
microalterations in microsatellite repeat number. Azole re-
sistance in A. fumigatus is an emerging problem and may 
develop during azole therapy.
I
nvasive  aspergillosis  in  immunosuppressed  patients  is 
difficult to diagnose, is problematic to treat, and results 
in a high mortality rate (1). Chronic and allergic pulmo-
nary and sinus aspergillosis are increasingly recognized in 
numerous  clinical  settings.  Treatment  with  itraconazole, 
voriconazole, and, recently, posaconazole is the backbone 
of therapy for these conditions because azoles are the only 
licensed class of oral drugs for treatment of aspergillosis 
(2,3). Amphotericin B and caspofungin are licensed intra-
venous agents for invasive aspergillosis but have limited 
utility for chronic and allergic aspergillosis.
Itraconazole  resistance  in  Aspergillus  spp.  was  first 
reported in 1997 in 3 clinical isolates obtained from Cali-
fornia in the late 1980s (4); since then, only a few clinical 
cases have been published (5–9). The emergence of itra-
conazole resistance alone is of concern, but widespread 
azole cross-resistance would be devastating.
The primary mechanism of resistance described for A. 
fumigatus clinical isolates is mutation in the target protein. 
The cyp51A gene encodes the target of azoles, lanosterol 
14α-demethylase, and this enzyme catalyzes a step in the 
biosynthetic pathway of ergosterol (an essential cell mem-
brane component of filamentous fungi). Mutations in the 
open reading frame of the cyp51A gene can result in struc-
tural alterations to the enzyme, which in turn may inhibit 
binding of drugs. Mutational hotspots confirmed to cause 
resistance have been characterized in the gene at codons 54 
(6,10–13), 220 (6,14,15), and 98 (16–18). Other mutations 
in the cyp51A gene have been reported, and additional re-
sistance mechanisms have been postulated (11,19,20). The 
environmental or antifungal pressures driving azole resis-
tance are unclear because few clinical azole-resistant Asper-
gillus strains have been studied in any detail; many reports 
simply describe individual patient cases. In this study, we 
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investigated the frequency of A. fumigatus itraconazole re-
sistance in a referral laboratory collection, defined the azole 
cross-resistance pattern, identified mutations in the cyp51A 
gene, and investigated any epidemiologic links between re-
sistant isolates.
Materials and Methods
Isolates
Isolates  deposited  in  the  Regional  Mycology  Labo-
ratory  Manchester  (RMLM)  culture  collection  (between 
1992 and 2007) were identified as A. fumigatus by macro- 
and  micromorphologic  characteristics.  All  isolates  were 
screened for growth at 50oC, thus confirming A. fumigatus 
and excluding A. lentulus. Aspergilli were subcultured onto 
Sabouraud glucose agar (Oxoid, Basingstoke, UK) for 48 
h at 37°C. Thirty-four azole-resistant and 5 susceptible iso-
lates from 17 patients were studied from the RMLM collec-
tion (prefixed F); 36 isolates were respiratory specimens, 1 
was cerebral, and 2 were from unknown sites. In addition, 
18 azole-resistant isolates from a single aspergilloma case-
patient (prefixed A, patient 3) collected at autopsy were 
also investigated.
Patients
Pertinent details from patients were extracted from the 
clinical records. All but 6 were under the care of 1 inves-
tigator (D.W.D.). Information was collected on underlying 
disease(s), type of aspergillosis, antifungal treatment, azole 
plasma levels, and characteristics of therapeutic failure.
Susceptibility Testing
Susceptibilities were determined by a modified Euro-
pean Committee on Antimicrobial Susceptibility Testing 
(EUCAST) method (21). The modification was a lower fi-
nal inoculum concentration (0.5 × 105 as opposed to 1–2.5 
× 105 CFU/mL). Isolates were tested at a final drug con-
centration range of 8, 4, 2, 1, 0.5, 0.25, 0.125, 0.06, 0.03, 
0.015  mg/L  against  itraconazole  (Research  Diagnostics 
Inc, Concord, MA, USA), voriconazole (Pfizer Ltd, Sand-
wich,  UK),  posaconazole  (Schering-Plough,  Kenilworth, 
NJ, USA), and amphotericin B (Sigma, Poole, UK). RPMI-
1640 (Sigma) was supplemented to 2% glucose (Sigma). 
Inocula were prepared in phosphate-buffered saline with 
0.05% Tween 80 (Sigma); Aspergillus spores were counted 
on a hemacytometer and adjusted to a final concentration 
of 5 × 104 CFU/mL. Inocula were loaded into flat-bottomed 
microtiter plates (Costar Corning, Lowell, MA, USA) and 
incubated at 37oC for 48 h. A no-growth end point was de-
termined by eye. MIC testing was performed on RMLM 
isolates in triplicate, and a consensus mean was derived 
(median or mode). Susceptibilities of the aspergilloma iso-
lates were determined once, except for 6 that were tested 3 
times. Values of >8 mg/L were classed as 16.
Clinical or epidemiologic breakpoints/cutoffs have not 
been declared by the Clinical and Laboratory Standards In-
stitute (CLSI) or EUCAST for azoles and Aspergillus spp. 
However, proposed epidemiologic cutoff values have been 
mooted for the latter (22), and we have recently proposed 
clinical breakpoints (23). Cutoffs used in this study were 
itraconazole and voriconazole >2 mg/L and posaconazole 
>0.5 mg/L (we have not defined an intermediate zone of 
susceptibility).
Sequencing
DNA was extracted by using commercially available 
kits (FastDNA Kit, Q-biogene, Cambridge, UK; Ultraclean 
Soil DNA Isolation Kit, MO BIO Laboratories Inc., Cam-
bridge; and DNeasy plant tissue kit, QIAGEN, Crawley, 
UK). The entire coding region of the cyp51A gene was am-
plified as previously described (7), except 3 mmol/L MgCl2 
was used and both strands were sequenced using 8 prim-
ers (7). Twelve of the aspergilloma (A) isolates were se-
quenced with only 1 primer, covering the region of interest 
in this case. Sequences were aligned against the sequence 
from an azole-susceptible strain (GenBank accession no. 
AF338659),  and  mismatches  were  identified  by  using 
AlignX (VectorNTI; Invitrogen, Paisley, UK). Mutations 
were confirmed by repeating the PCR and sequencing both 
strands by using the closest 2 primers. Isolates with an al-
teration in the cyp51A gene at codon 98 were also investi-
gated for promoter modifications by sequencing this region 
(17). GenBank accession numbers for the cyp51A sequenc-
es determined in this study are EU807919−EU807922 and 
FJ548859−FJ548890.
Microsatellite Typing
Six microsatellite loci (3A, 3B, 3C, 4A, 4B, 4C) were 
amplified as previously described (24). Initially some ampli-
cons were sequenced, whereas later ones were sized by using 
capillary electrophoresis on an ABI PRISM 3130×l Genetic 
Analyzer (Applied Biosystems, Warrington, UK). Electro-
phoresis data were analyzed by using Peak Scanner Software 
version 1.0 (Applied Biosystems); amplicon sizes were ad-
justed by using a correction factor derived from sequenced 
alleles to determine the actual sizes of alleles (25). Concat-
enated  multilocus  microsatellite  genotypes  were  created 
for each isolate and used to generate allele-sharing genetic 
distance matrices, DAS. Here, DAS = 1 – (the total number 
of shared alleles at all loci / n), where n is the total number 
of loci compared (26). Subsequently, phylogenetic compari-
sons using 5 of the loci (not 3B) were performed with the 
software PAUP* 4.0 (www.paup.csit.fsu.edu) by using the 
neighbor-joining  algorithm  with  the  minimum-evolution   
option active. The strength of support for relationships was 
assessed by using 1,000 bootstrap resamples of the dataset.
  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 15, No. 7, July 2009  1069 RESEARCH
Results
Susceptibility
The susceptibility of 519 A. fumigatus RMLM culture 
collection isolates was determined. All isolates were tested 
for  susceptibility  against  itraconazole  and  amphotericin 
B; 456 and 118 isolates were also tested against voricon-
azole  and  posaconazole,  respectively.  Subsequently,  all 
itraconazole-resistant isolates were tested against voricon-
azole and posaconazole. Geometric means, ranges, MIC50 
(median MIC), and MIC90 (90% of the isolates tested had 
a MIC at or below this level) values are shown in Table 1. 
Amphotericin B susceptibility was retained in the 34 itra-
conazole-resistant isolates tested. Of these, 65% (22) were 
cross-resistant to voriconazole and 74% (25) were cross-
resistant to posaconazole. We did not identify any isolates 
that were resistant to voriconazole or posaconazole while 
remaining susceptible to itraconazole.
Five percent of 400 isolates were resistant to itracon-
azole (when duplicate isolates from the same patient with 
similar susceptibility profiles were removed from the analy-
sis). The overall frequency of itraconazole resistance in this 
collection (with repeat specimens included) was 7% (n = 
519). The first case of azole resistance in this collection was 
seen in 1999. The frequency of resistance since 2004 (8%) 
has  increased  significantly  (Fisher  exact  test,  p<0.001), 
compared with the period prior to 2004 (Figure 1).
Azole Exposure in Patients with Azole-Resistant  
Isolates and Response to Therapy
Of the 17 patients identified for respective review, lim-
ited data were available for 3 patients. Of the remaining 
14 patients with antifungal data (Table 2), azole exposure 
of 1–30 months before the identification of the first resis-
tant isolate was evident for all except patient 7. Thirteen 
patients received itraconazole as initial therapy, and 12 of 
these were evaluable. Infections failed to respond to thera-
py in 7 itraconazole-treated patients (i.e., their disease pro-
gressed), although 3 patients appeared to improve before 
their conditions began to deteriorate. Infections failed to 
improve with azole therapy in 5 patients (i.e, their disease 
remained stable), and no patient had a sustained response 
to therapy. Nine of the 12 patients had at least 1 therapeu-
tic concentration of itraconazole (>5.0 mg/L) documented 
at steady state during their treatment course (online ex-
panded version of Table 2, available from www.cdc.gov/
EID/content/15/7/1068-T2.htm). The infection in patient 1 
(treated with voriconazole only for 18 months) failed ther-
apy, and the 1 isolate identified had MICs of >8 mg/L for 
both itraconazole and voriconazole.
Of the 14 patients with available data, 2 had invasive 
disease; 9 had chronic diseases with >1 aspergillomas; 2 had 
allergic bronchopulmonary aspergillosis; and 1 had Asper-
gillus bronchitis. At least 5 of the patients died of progressive 
infection, despite alternative therapies for some.
Mutations in the cyp51A Gene
A summary of Cyp51A amino acid substitutions and 
azole cross-resistance patterns identified in 34 resistant iso-
lates from our clinical culture collection is shown in Table 
3 and listed by line in the online Appendix Table (available 
from www.cdc.gov/EID/content/15/7/1068-appT.htm). The   
sequences of all 5 azole-susceptible isolates examined were 
identical to that of a previously published cyp51A gene se-
quence from an azole-susceptible isolate (AF338659). No 
cyp51A  mutations  were  found  in  3  itraconazole-resistant 
isolates (from 2 patients). In addition to the L98H substitu-
tion, 2 isolates from 2 patients had a 34-bp sequence that 
was duplicated in the promoter region (16,17) of the cyp51A 
gene. One isolate had 2 amino acid substitutions, H147Y 
and G448S. Three isolates from 2 patients had the same 6 
mutations, 3 nonsynonymous ones (F46Y, M172V, E427K), 
along with 3 synonymous (silent) alterations at codons 89, 
358, and 454 (data not shown), and an isolate from a third 
patient had additional mutations (N248T, D255E) as well as 
these 6. Four novel mutations were found (H147Y, P216L, 
Y431C, and G434C). The isolate bearing the P216L muta-
tion was resistant to itraconazole and posaconazole, where-
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Table 1. MICs for 519 Aspergillus fumigatus isolates from RMLM culture collection, 1992–2007* 
Susceptibility results, mg/L 
Itraconazole Voriconazole Posaconazole Amphotericin B
Isolate group
(no. isolates) 
GM
(range)
MIC50/
MIC90
GM
(range)
MIC50/
MIC90
GM
(range)
MIC50/
MIC90
GM
(range)
MIC50/
MIC90
RMLM collection 
(519), 1992–2007
0.46
(<0.015–>8)
0.25/2 0.92
(0.125–>8)
1/2 0.22
 (0.03–>8)
0.125/2 0.34
(0.06–2)
0.25/1
Azole resistant (34) 16.0
(>8)
>8/>8 3.69
(0.125–>8)
4/>8 1.70
(0.125–>8)
1/>8 0.22†
 (0.06–0.5)
0.25/0.5
Percentage resistant 100% 65% 74% 0%
Aspergilloma (18) 16.0
 (>8) 
>8/>8 2.16
(0.5–4.0)
4/4 1.92
(0.125–>8)
1/>8 0.10‡
 (0.06–0.125)
0.125/
0.125
*RMLM, Regional Mycology Laboratory Manchester; GM, geometric mean. Values >8 mg/L were classed as 16 mg/L for GM analysis. See also the online 
Appendix Table, available from www.cdc.gov/EID/content/15/7/1068-appT.htm. 
†n = 28. 
‡n = 6. Azole Resistance in A. fumigatus
as the isolates with Y431C and G434C showed pan-azole 
resistance phenotypes.
Patient 3 had 2 respiratory samples taken while she 
was alive, in addition to 18 aspergilloma isolates sampled 
at autopsy. All isolates were resistant to itraconazole (>8 
mg/L), and 1 of 2 different mutations at codon 220 was 
detected in the cyp51A gene. Isolates with a methionine-to-
lysine substitution were highly cross-resistant to voricon-
azole (4 mg/L) and posaconazole (>8 mg/L), whereas those 
with an alteration to threonine had variable voriconazole 
(0.5–4 mg/L) and posaconazole (0.125–1 mg/L) MICs.
Microsatellite Typing
 The relatedness of isolates obtained from patients 3, 
4, 5, 6, 8, 9, and 13 were compared by microsatellite typ-
ing (Figure 2). The isolates from 5 patients consisted of a 
susceptible/resistant pair, whereas an overlapping group of 
4 patients had more than 1 cyp51A mutation. All isolates 
were from the lower respiratory tract, except the resistant 
isolate from patient 5, which was from a cerebral lesion.
Multiple isolates from 5 of 7 patients had identical or 
nearly identical genotypes. The isolates from 2 of these 5 
patients (3 and 6) differed by 1 and 2 trinucleotide repeat 
units, respectively, at the most polymorphic locus (3A). 
Three matched sets (isolates pre- and postdevelopment of 
resistance) were identified, where resistance almost cer-
tainly evolved from an originally susceptible strain.
Figure 2 shows an unrooted tree of the phylogenetic re-
lationships, derived from 5 of the 6 microsatellite markers, 
for the isolates from these 7 patients plus 18 A. fumigatus   
isolate  controls.  Only  bootstrap  values  >90  are  shown. 
Strains from these 7 patients are distributed among other 
clinical isolates; statistically supported clustering is not evi-
dent. Therefore, none of the azole-resistant isolates have 
been  transmitted  from  patient  to  patient,  indicating  that 
they have all evolved independently from different original 
strains. The only statistically supported clades contain iso-
lates that only differ from each other by 1 of the 5 markers.
Discussion
Itraconazole resistance and azole cross-resistance in 
Aspergillus spp. have been reported infrequently, which 
suggests that they are infrequent events to date. A con-
tributing factor to this low prevalence has been variabil-
ity in testing between laboratories. Since the initial report 
of resistance in isolates collected before the licensure of 
itraconazole,  substantial  improvements  in  susceptibility 
testing  methods  that  allow  confidence  in  reported  azole 
MICs have been implemented. Recommended methods are 
now promulgated by the CLSI method M38-A2 (27) and   
EUCAST  (21),  and  work  is  ongoing  to  establish  inter-
nationally agreed interpretative cutoffs (22) and clinical 
breakpoints (23).
By using such methods, some researchers have docu-
mented and published the frequency of itraconazole resis-
tance in clinical A. fumigatus isolates (8,28–32); frequency 
ranged between 2% and 6%. However, most of these stud-
ies included fewer isolates (<200) than our study (519) and 
covered the pre-2004 era. The frequency of itraconazole 
resistance  in  our  collection  before  2004  was  1%;  since 
2004, however, it has been remarkably high at 8%. The 
high frequency probably reflects, at least in part, the spe-
cialized referral base for patients with chronic and allergic 
aspergillosis at our center, although there has been no ma-
terial change in catchment area in the past decade. Referral 
numbers are rising, however, and susceptibility testing of 
isolates of patients receiving therapy has been more fre-
quent since 2003.
Another remarkable aspect of this study is the diver-
sity of cyp51A mutations. Both previously published and 
novel alterations were identified in our resistant isolates 
(Table 3). In contrast, a recent series of 32 itraconazole-
resistant isolates from the Netherlands was published; 94% 
had  the  same  2  alterations:  an  L98H-aa  substitution  in   
Cyp51A, in combination with a duplication in the promoter 
region (32). This combination of mutations was found in 2 
of our isolates from 2 patients.
Several  authors  have  identified  hot-spot  regions  as-
sociated with resistance in clinical isolates at codons 54 
(6,10–13,22), 98 (16–18,22,32,33), and 220 (6,14,15,22,32) 
in the cyp51A gene. We previously reported an alteration 
at codon 138 (G138C) in multiple isolates from 1 patient 
(7). A single clinical isolate with a mutation at codon 448   
(G to S) has also been previously reported (34). In addition, 
G138R and G448S mutants have been generated in the   
  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 15, No. 7, July 2009  1071 
Figure 1. Azole resistance in clinical Aspergillus fumigatus isolates 
received  in  the  Regional  Mycology  Laboratory  Manchester,  UK, 
1997–2007. Overall azole resistance for each year is shown above 
each  column  as  a  percentage.  Data  do  not  include  sequential 
isolates from the same patient.RESEARCH
laboratory  and  were  azole  resistant  (35).  Mutations  in 
codons 46, 172, 248, 255, and 427 have been found in 
azole-susceptible strains by us (A. Albarrag, unpub. data) 
and others (22) and so are not associated with resistance. 
The resistant isolates with these mutations must therefore 
have  another  resistance  mechanism.  Four  novel  cyp51A 
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Table 2. Clinical information for 14 patients with azole-resistant Aspergillus fumigatus infections* 
Patient 
no.  Location 
No. 
isolates 
Aspergillus 
disease  Other diseases, y 
Treatment, 
duration 
Serum azole 
levels, mg/L†  Outcome/survival 
1  Cambridge, 
UK 
1  CCPA with 
aspergilloma
Breast cancer, 1990; M. 
malmoense pulmonary 
tuberculosis, 1999 and 2005
Vori 200–400 
mg, 18 mo 
ND  Clinical and 
radiologic failure/ 
alive 
2  Copenhagen, 
Denmark 
1  ABPA  CF, concomitant bacterial 
colonization with 
Staphylococcus aureus and 
Achromobacter 
Itra 200 mg, 
14 mo (plus 
previous 
courses) 
ND  Unknown/alive 
3  Manchester, 
UK 
2‡  CCPA with 
aspergilloma 
CFPA 
Pulmonary TB with residual 
bilateral UL scarring and 
LUL cavity, 1986; smoke 
inhalation, 1989 
Itra 400 mg, 
90 mo 
15.0–26.0§  Clinical 
failure/died 
4  Manchester, 
UK 
3  CCPA with 
aspergilloma
COPD, squamous cell 
carcinoma with LUL 
segmentectomy, 1992 
Itra 400 mg, 
>2 mo
2.9–11.3  No 
Improvement/died
5  Montreal, 
Quebec, 
Canada 
2  Cerebral 
aspergillosis, 
1998 Nov 
AML-M2, 1997; RUL 
lobectomy, 1997; AlloHSCT, 
1998; GVHD 
Itra 400 mg, 
4 mo 
ND  Regression of 
cerebral abscess, 
IPA with 
respiratory 
failure/died 
6  Manchester, 
UK 
2  CCPA with 
aspergilloma
COPD, M. szulgai 
pulmonary infection, 2003; 
celiac disease 
Itra 200–400 
mg, 1 mo  
<0.8 (200 mg), 
5.3–7.7 (400 
mg) 
Clinical 
failure/died 
7  Manchester, 
UK 
1  Acute 
invasive 
pulmonary 
infection 
COPD, 
possible bronchiectasis 
Itra 600–400 
mg, 1 mo; 
vori 400 mg; 
12 d 
17.0–21.0 (itra)  No improvement, 
switched to vori, 
developed 
toxicity/died 
without IPA 
8  Northampton, 
UK 
2  ABPA  Bronchiectasis, asthma, 
AVR, hypermobility 
syndrome; M. xenopi 
pulmonary infection, 2007 
Itra 200–400 
mg, 9 mo 
0.0–5.2  Initial 
improvement, 
then failure/alive 
9  Liverpool, UK  12  CCPA with 
bilateral 
aspergilloma, 
CFPA 
Pulmonary sarcoidosis, 
1988 
Itra 200–400 
mg, 30 mo 
0.9–10.3  Clinical 
failure/died 
10  Manchester, 
UK 
2  Aspergillus 
bronchitis 
Bronchiectasis, 
onychomycosis, 2007; Į-1-
antitrypsin deficiency 
Itra 400 mg 
pulse, 3 mo 
ND  Itra resistance 
identified, treated 
with posa/alive 
11  Manchester, 
UK 
2  CCPA with 
aspergilloma
RUL pneumonia, 2002  Itra 400 mg, 
1.5 mo 
20.0–>25.6  No 
improvement/alive
12  Manchester, 
UK (Malawi 
origin) 
1  CCPA with 2 
aspergilloma
Pulmonary TB, 1995; HIV 
positive, HAART 
Itra 400 mg, 
18 mo 
2.5–8.4  Improvement then 
progression/alive 
13  Preston, UK  4  CCPA with 
aspergilloma
COPD, bronchiectasis, M. 
avium pulmonary infection, 
2002 and 2006 
Itra 600 mg, 
10 mo 
2.6–4.5  Progression/alive 
14  Birkenhead, 
UK 
1  CCPA with 
LUL 
aspergilloma
Sarcoidosis, COPD, celiac 
disease; aspergilloma 
removed as part of left lung 
transplant, 2007¶ 
Itra 400 mg, 
11 mo 
13.8–17.8  Unchanged, 
switched to 
vori/unknown 
*CCPA, chronic cavitary pulmonary aspergillosis; M., Mycobacterium; vori, voriconazole; ND, not determined; ABPA, allergic bronchopulmonary 
aspergillosis; CF, cystic fibrosis; itra, itraconazole; CFPA, chronic fibrosing pulmonary aspergillosis; TB, tuberculosis; UL, upper lobe; LUL, left upper lobe; 
COPD, chronic obstructive pulmonary disease; AML, acute myeloid leukemia; RUL, right upper lobe; AlloHSCT, allogeneic haematopoietic stem cell 
transplant; GVHD, graft versus host disease; IPA, invasive pulmonary aspergillosis; AVR, aortic valve replacement; posa, posaconazole; HAART, highly 
active antiretroviral therapy. An expanded version of this table, showing complete data on all 17 patients, is available online at (www.cdc.gov/EID/content/ 
15/7/1068-T2.htm). 
†Determined by bioassay (target range 5–15 mg/L). 
‡Plus aspergilloma isolates studied, taken at autopsy. 
§Received a generic formulation of itra, resulting in lower concentrations (i.e., 4.6 mg/L) and then probably was noncompliant at end of treatment period. 
¶Successfully completed with vori treatment. Azole Resistance in A. fumigatus
mutations, 3 of which were unassociated with any other 
mutations (in codons 147, 216, 431, and 434), were identi-
fied in this series, although their association with resistance 
remains to be confirmed experimentally. The H147Y sub-
stitution is probably unimportant for resistance because it 
was found with G448S in 1 isolate and the cross-resistance 
profile of this isolate was identical to an isolate that had 
only G448S. We did not find any examples of previously 
reported mutations at codons 297 and 495 (17,32) or 22, 
394, 491, and 440 (14) in our collection. Three of our resis-
tant isolates had no mutations in their cyp51A gene, indicat-
ing the presence of other resistance mechanisms.
The  position  and  type  of  amino  acid  substitution 
within the Cyp51A protein determines the pattern of azole 
cross-resistance (Table 3), which is consistent with pre-
dicted structural properties of the demethylase enzyme and 
its interaction with chemically different azole drugs (36). 
Resistance to itraconazole is usually associated with a re-
duction in posaconazole susceptibility, predictably because 
the 2 drugs are structurally similar; they have variably el-
evated posaconazole MICs compared with wild type iso-
lates (22,30). Many of the isolates reported here reflect this 
MIC shift. Isolates with alterations at codons 98 (including 
the duplication in the promoter region), 138, 431, and 434 
demonstrated cross-resistance  to  voriconazole and  posa-
conazole. All isolates with substitutions at codons 54 and 
216 remained susceptible to voriconazole. Some isolates 
in this study showed cross-resistance between itraconazole 
and voriconazole and not posaconazole, unlike the results 
in previous reports (22,32). However, this cross-resistance 
could be because of differing breakpoints; therefore, deter-
mination of an internationally agreed cutoff for posacon-
azole will be necessary to guide clinicians. No difference in 
amphotericin B MICs was seen in our azole-resistant iso-
lates compared with susceptible ones, although the clinical 
utility of MIC testing of amphotericin B in Aspergillus spp. 
is suboptimal.
More than 1 azole-resistant A. fumigatus isolate was 
obtained from 6 of the 17 patients described. Microsatellite 
typing demonstrated that the isolates from each patient had 
evolved from a single original strain, because they were 
either identical at 6 markers or differed only in the most 
polymorphic marker. The resistant isolates from 4 patients 
had different cyp51A mutations. Given that a single colony 
is picked from the primary isolation plate and referred for 
susceptibility testing, additional mutants may have been 
found had multiple colonies been tested. Within this data-
set, the chance of 2 isolates being identical by chance alone 
within a recombining population are infinitesimal  given the 
high allelic variability that we observed (mean number of 
alleles per locus = 14; p value recovering the same multilo-
cus genotype twice ≈145). The existence of susceptible and 
resistant isolates that are genetically identical from 3 pa-
tients, and the phylogeny performed on the multiple-resis-
tant isolates from an additional 4 patients, almost certainly 
indicates that the evolution of azole resistance has occurred 
in these patients independently and repeatedly from unre-
lated strains. The presence of genetically identical isolates 
with different cyp51A codon mutations in 3 patients (and 1 
almost identical) suggests that they must have evolved in-
dependently from the same original strain, because the re-
sistance mutations are not being accumulated sequentially 
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Table 3. Cyp51A amino acid substitutions and associated cross-resistance patterns in azole-resistant RMLM Aspergillus fumigatus
isolates*
MIC, mg/L†
Cyp51A codon No. patients No. isolates
Amino acid 
substitutions Itraconazole Voriconazole Posaconazole
F46‡ 3 4‡ Y >8 2–4 0.125–0.5
G54 4 5 E, R, V >8 0.125–1 1–>8
L98+TR 2 2 H >8 8 1–2
G138 1 10 C >8 8–>8 2–>8
H147§ 1 1§ Y >8 >8 0.5
M172‡ 3 4‡ V >8 2–4 0.125–0.5
P216 1 1 L >8 1 1
M220 3 4 K, T >8 1–4 0.5–>8
N248‡ 1 1 T >8 2 0.25
D255‡ 1 1 E >8 2 0.25
E427‡ 4 5‡ G, K >8 2–4 0.125–0.5
Y431 1 1 C >8 4 1
G434 1 1 C >8 4 1
G448 2 2 S >8 >8 0.5–1
No substitutions 2 3 NA >8 2–8 0.25–1
*RMLM, Regional Mycology Laboratory Manchester; TR, tandem repeat in cyp51A promoter; NA, not applicable. Synonymous mutations not shown. 
Some mutations are associated with resistance but may not be causal (see text). 
†Putative cut-off values for resistance are itraconazole and voriconazole >2 mg/L and posaconazole >0.5 mg/L. 
‡F46Y found with M172V and E427K in 4 isolates along with 3 silent mutations. E427G seen alone in 1 isolate. N248 and D255 found in combination with 
46/172/427 in 1 isolate. 
§Found with G448S in 1 of 2 isolates. RESEARCH
as has been shown to happen in Candida albicans (37). The 
isolates from 2 patients had differing numbers of repeats of 
microsatellite marker 3A, which is further proof that strains 
are evolving in the lung. In contrast, Snelders et al. (32) 
suggested that many of their patients were infected with a 
primary resistant strain from the environment.
The referral base for these isolates includes a special-
ized clinical service for the management of aspergillosis. 
Many of our resistant isolates came from this group, in 
particular from 9 patients with chronic cavitary pulmonary 
aspergillosis with >1 aspergillomas, which may explain the 
high frequency of resistance in our center. Because sur-
gery is not an option for most patients with chronic cavi-
tary pulmonary aspergillosis, these patients usually require 
long-term (if not lifelong) antifungal therapy, under which 
conditions as we have shown, strains of A. fumigatus may 
evolve resistance. Another contributory explanation could 
be our systematic application of susceptibility testing of 
Aspergillus spp. isolates in all cases in which treatment is 
to be given.
In 6 of 10 patients, steady state itraconazole plasma 
level data were at or above minimum therapeutic levels 
(i.e., <5 mg/L), as determined by bioassay (38,39). Low 
plasma levels of itraconazole were attributable to limited 
bioavailability in some patients, low doses (i.e., 200 mg 
daily, the standard UK registered dose), drug interactions 
in patients with concomitant atypical mycobacterial infec-
tion, and use of generic itraconazole (40). Low plasma lev-
els of itraconazole, in combination with the high proportion 
of patients in this study with prior azole exposure (13 out 
of 14), indicates that resistance primarily emerged during 
or after azole therapy.
Our observations are of concern on several fronts. We 
found a sudden rise in the frequency of azole resistance in 
A. fumigatus since 2004, and many isolates showed cross-
resistance between all the currently licensed azole options. 
Clinical data indicate that resistance has occurred during 
and after azole therapy in all but 1 of these cases. The in-
fections caused by azole-resistant isolates fail therapy or at 
best do not respond. The molecular epidemiology shows 
that resistance evolved in infecting strains within the lung, 
rather than by superinfection with a resistant stain from the 
environment. Because azoles are the only useful class of 
oral drugs for aspergillosis (and many other serious fila-
mentous fungal infections), clinical management of these 
chronically infected cases is therefore problematic. Vigi-
lance is called for to identify azole-resistant aspergilli, and 
novel classes of oral antifungal would be welcome for those 
infected with azole-resistant strains.
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